GLP-1 Products for Obesity and Diabetes Research

GLP-1 MOA-reflective Assays to Expedite Development of Next-generation Therapeutics for Obesity and Diabetes

Glucagon-like peptide-1 receptor (GLP-1R) is a clinically validated target at the forefront of obesity and type 2 diabetes (T2D) drug discovery. GLP-1 therapeutics that activate GLP-1R have transformed the treatment landscape, delivering potent glucose-lowering, appetite-suppressing, and weight-reducing effects. Blockbuster drugs such as semaglutide (Ozempic®, Wegovy®) and liraglutide (Saxenda®) have not only demonstrated the power of GLP-1R agonism but have also spurred a wave of innovation in incretin-based therapies.

In recent years, drug discovery has expanded beyond single-target GLP-1R agonists toward multi-receptor strategies designed to enhance efficacy and address a broader range of metabolic comorbidities. Dual and triple agonists — such as tirzepatide (GLP-1/GIP) and retatrutide (GLP-1/GIP/GCG) — as well as combination approaches involving Amylin or PYY, are reshaping the therapeutic landscape.

Eurofins DiscoverX® offers a comprehensive portfolio of GLP-1 product solutions to accelerate drug discovery and development for obesity and diabetes. The portfolio includes GLP-1 assays, including human and ortholog GLP-1R cell lines for reproducible functional studies, ready-to-use eXpress assay kits for quick analysis in early discovery, and qualified bioassays for potency testing that meet regulatory standards. The diverse assay formats offer interrogation of multiple mechanisms of action (MOA), including cAMP signaling, β-arrestin recruitment, and receptor internalization for thorough pharmacological profiling. These GLP-1 product solutions are designed to deliver MOA-reflective data at every stage of the development cycle — from early screening and lead optimization to clinical development, commercialization, and stability testing.

Whether you are working on a GLP-1 monotherapy or a multi-target incretin approach, rely on Eurofins DiscoverX products to ensure scientific rigor, regulatory alignment, and accelerated timelines.

Product Highlights
  • Comprehensive GLP-1R Assay Portfolio – Human and ortholog cell lines, eXpress kits, qualified bioassays, and detection reagents covering every stage of drug discovery and development
  • Multiple MOA Formats – Measure ligand activity across cAMP signaling, β-arrestin recruitment, and receptor internalization for complete pharmacological profiling
  • Regulatory-ready Solutions – Qualified bioassays for potency and bio-identity testing, widely cited in publications, patents, and regulatory submissions
  • Designed for Evolving Therapies – Supports GLP-1R monotherapies and multi-target incretin programs

Consider Eurofins DiscoverX’s custom development capabilities for custom cell lines, assays, & enzyme development.

* Ozempic, Wegovy, & Saxenda are registered trademark owned by Novo Nordisk A/S.
SHOP PRODUCTSREAD APP NOTEVIEW WEBINARREVIEW POSTERSEE PRESENTATION

Products

Eurofins DiscoverX provides a full suite of GLP-1 tools to support obesity and diabetes drug discovery, including human and ortholog cell lines, ready-to-use eXpress assay kits, membrane preparations, as well as qualified and target-based bioassays for potency and regulatory-compliant testing.
 

Product Types

  • GLP-1 Bioassay Kits – Ready-to-use cell-based assay kits with a simple, homogeneous protocol. These physiologically relevant, robust bioassays are fit-for-purpose for screening and characterization applications, as well as for potency testing in commercialization quality control (QC) lot release programs.
  • GLP-1 Stable Cell Lines – Stable cell lines (continuous culture) developed to reflect the target’s mechanism of action (cAMP, β-arrestin, and internalization) with a drugs’ interaction in a standard cell line background.
  • GLP-1 eXpress Assay Kits – Ready-to-use cell-based assay kits for quick analysis and implementation in early discovery phases for screening applications, proof-of-concept, MOA confirmation (cAMP, β-arrestin, and internalization), and rank-ordering studies.
  • GLP-1 Membrane Preparations – Derived from proprietary stable recombinant cells ensuring high levels of receptor surface expression. Ideal for screening ligand binding affinities.

 

Applications

  • GLP-1 cAMP Assays – Explore a full suite of products designed to quantify cAMP in response to GLP-1R activation.
  • GLP-1 β-Arrestin Products – Characterize GLP-1R function and ligand bias with β-arrestin cell lines and eXpress assay kits.
  • GLP-1 Internalization Assays – To support GLP-1R internalization studies, Eurofins DiscoverX offers activated and total GLP-1R Internalization tools in both stable cell line formats and eXpress assay kits.